Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics
ASMB Price/Volume Stats
| Current price | $12.65 | 52-week high | $20.04 |
| Prev. close | $13.36 | 52-week low | $7.69 |
| Day low | $12.00 | Volume | 29,386 |
| Day high | $13.43 | Avg. volume | 26,944 |
| 50-day MA | $13.03 | Dividend yield | N/A |
| 200-day MA | $11.27 | Market Cap | 69.36M |
ASMB Stock Price Chart Interactive Chart >
Assembly Biosciences, Inc. (ASMB) Company Bio
Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.
Latest ASMB News From Around the Web
Below are the latest news stories about ASSEMBLY BIOSCIENCES INC that investors may wish to consider to help them evaluate ASMB as an investment opportunity.
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023. The Company granted Dr. Gaggar non-qualified stock options to purchase 500,000 shares of the Company’s common stock with an exercise price of $0.85 per share, the closing pri |
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Li |
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent UpdatesEstablished partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyondNow anticipate four development candidates from expanded pipeline in clinical development by the end of 2024Named Anuj Gaggar, MD, PhD, as chief medical officer $100 million upfront payment and investment received from Gilead in October extends projected cash runway into 2H 2025 SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: A |
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar i |
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement! |
ASMB Price Returns
| 1-mo | -5.46% |
| 3-mo | 17.12% |
| 6-mo | 29.16% |
| 1-year | 1.36% |
| 3-year | -75.54% |
| 5-year | -93.31% |
| YTD | 28.54% |
| 2023 | -36.92% |
| 2022 | -44.21% |
| 2021 | -61.49% |
| 2020 | -70.43% |
| 2019 | -9.55% |
Continue Researching ASMB
Want to see what other sources are saying about Assembly Biosciences Inc's financials and stock price? Try the links below:Assembly Biosciences Inc (ASMB) Stock Price | Nasdaq
Assembly Biosciences Inc (ASMB) Stock Quote, History and News - Yahoo Finance
Assembly Biosciences Inc (ASMB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...